ArticleJournal of orthopaedic surgery and research2020
Umbilical cord-derived Wharton's jelly for regenerative medicine applications.
Article in Journal of orthopaedic surgery and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Open Label Dose-Ranging Study to Assess the Safety, Tolerability, Preliminary Efficacy, and Dose Effect of CFL001 Cord Blood Product in Patients With Symptomatic Sacroiliac Joint Syndrome
Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Transplantation of three mesenchymal stem cells for knee osteoarthritis, which cell and type are more beneficial? a systematic review and network meta-analysis.Journal of orthopaedic surgery and research · 2024Pooled it
- Human umbilical cord mesenchymal stem cells promoting knee joint chondrogenesis for the treatment of knee osteoarthritis: a systematic review.Journal of orthopaedic surgery and research · 2023Pooled it
- Cryopreserved umbilical allograft (equicenta® CTM) improves clinical outcomes compared with clinician-selected standard of care in performance horses: a pragmatic prospective controlled trial.Frontiers in veterinary science · 2026Trial
- Comparative Evaluation of Decellularized Human Amniotic Membrane and Wharton's Jelly in a Rat Model of Myocardial Infarction: Experimental Study.Current issues in molecular biology · 2026Article
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
- Wharton's jelly-derived mesenchymal stem cells promote the survival and early development of pre-antral follicles.Journal of assisted reproduction and genetics · 2026Article
- An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions.Biomedicines · 2026Article
- Methods and Technical Issues for Optimizing the Production of Hydrogels Containing Decellularized Wharton's Jelly.ACS biomaterials science & engineering · 2026Article
- LncRNA TUG1 promotes osteogenic differentiation of human umbilical cord mesenchymal stem cells by regulating miR-138/SIRT1 axis.Journal of orthopaedic surgery and research · 2026Article
- Wharton's jelly mesenchymal stem cell-derived exosomes promote odontogenic differentiation of dental pulp stem cells: A cell-free strategy for regenerative endodontics.Journal of conservative dentistry and endodontics · 2026Article
- A Novel Combined Therapeutic Approach to Endometriosis: Exosomes Derived from Human Wharton's Jelly Mesenchymal Stem Cells and Etanercept.Current molecular medicine · 2026Article
- An Observational Cohort Study of Wharton's Jelly Tissue Allografts for Posterior Tibial Tendon Degeneration.Biomedicines · 2025Article
- Wharton's Jelly Tissue Allografts for Tearing in the Plantar Fascia: A Case Series.Biomedicines · 2025Article
- Bio fluid exosomes: promises, challenges, and future directions in translational medicine.Journal of translational medicine · 2025Review
- Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study.BMC medicine · 2025Article
- TNFRSF11B-modified umbilical cord mesenchymal stem cells as a novel strategy for bone-related diseases by suppressing osteoclast activity.Journal of orthopaedic surgery and research · 2025Article
- Cell-free regenerative medicine: identifying the best source of mesenchymal stem cells for skin therapy in Systemic Sclerosis.Frontiers in cell and developmental biology · 2025Article
- In vitro and in vivo assessment of a non-animal sourced chitosan scaffold loaded with xeno-free umbilical cord mesenchymal stromal cells cultured under macromolecular crowding conditions.Biomaterials and biosystems · 2024Article
- Exosomes derived from platelet-rich plasma present a novel potential in repairing knee articular cartilage defect combined with cyclic peptide-modified β-TCP scaffold.Journal of orthopaedic surgery and research · 2024Article
- Small Extracellular Vesicles and Oral Mucosa: The Power Couple in Regenerative Therapies?Cells · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundThe last decade has seen an explosion in the interest in using biologics for regenerative medicine applications, including umbilical cord-derived Wharton's Jelly. There is insufficient literature assessing the amount of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes in these products. The present study reports the development of a novel Wharton's jelly formulation and evaluates the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes.
methodsHuman umbilical cords were obtained from consenting caesarian section donors. The Wharton's jelly was then isolated from the procured umbilical cord and formulated into an injectable form. Randomly selected samples from different batches were analyzed for sterility testing and to quantify the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles.
resultsAll samples passed the sterility test. Growth factors including IGFBP 1, 2, 3, 4, and 6, TGF-α, and PDGF-AA were detected. Several immunomodulatory cytokines, such as RANTES, IL-6R, and IL-16, were also detected. Pro-inflammatory cytokines MCSFR, MIP-1a; anti-inflammatory cytokines TNF-RI, TNF-RII, and IL-1RA; and homeostatic cytokines TIMP-1 and TIMP-2 were observed. Cytokines associated with wound healing, ICAM-1, G-CSF, GDF-15, and regenerative properties, GH, were also expressed. High concentrations of hyaluronic acid were observed. Particles in the extracellular vesicle size range were also detected and were enclosed by the membrane, indicative of true extracellular vesicles.
conclusionThere are numerous growth factors, cytokines, hyaluronic acid, and extracellular vesicles present in the Wharton's jelly formulation analyzed. The amount of these factors in Wharton's jelly is higher compared with other biologics and may play a role in reducing inflammation and pain and augment healing of musculoskeletal injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.